Table 2 Uncorrelated and significantly differentially methylated CpG sites between paired tumour and adjacent benign diagnostic samples.

From: Detection of differentially methylated CpGs between tumour and adjacent benign cells in diagnostic prostate cancer samples

CpG

Chr

Position

Gene

Gene Region

Bonferroni

deltaβ

cg11213690

7

149,112,402

Intergenic

Intergenic

2.92E−18

0.48

cg06832339

7

23,842,119

STK31

Body

4.19E−18

0.42

cg09414673

7

1,022,797

CYP2W1

TSS200

1.10E−17

0.45

cg05415131

11

58,940,866

DTX4

Body

5.06E−17

0.54

cg26310256

23

13,588,301

EGFL6

Body

1.09E−16

0.52

cg03217795

16

23,847,556

PRKCB

1st Exon

1.17E−16

0.42

cg03225210

7

143,579,951

FAM115A

5'UTR

1.79E−16

0.49

cg16670497

1

110,210,913

GSTM2

Body

2.52E−16

0.54

cg14621217

17

80,944,134

B3GNTL1

Body

6.20E−16

0.45

cg16709294

14

70,235,567

SFRS5; LOC100289511

Body; TSS1500

6.81E−16

0.43

cg21918559

23

36,976,052

Intergenic

Intergenic

9.36E−16

0.48

cg14775423

4

57,372,356

ARL9

5'UTR

1.74E−15

0.42

cg14179575

18

13,826,399

MC5R

1st Exon

2.43E−15

0.42

cg05057720

14

38,724,675

CLEC14A

1st Exon

4.26E−15

0.5

cg19713460

22

39,745,530

SYNGR1

TSS1500

6.48E−15

0.44

cg00927554

12

95,941,920

USP44

5'UTR

4.16E−11

0.41